287 related articles for article (PubMed ID: 33745946)
1. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
Inoue A; Robinson FS; Minelli R; Tomihara H; Rizi BS; Rose JL; Kodama T; Srinivasan S; Harris AL; Zuniga AM; Mullinax RA; Ma X; Seth S; Daniele JR; Peoples MD; Loponte S; Akdemir KC; Khor TO; Feng N; Roszik J; Sobieski MM; Brunell D; Stephan C; Giuliani V; Deem AK; Shingu T; Deribe YL; Menter DG; Heffernan TP; Viale A; Bristow CA; Kopetz S; Draetta GF; Genovese G; Carugo A
Gastroenterology; 2021 Jul; 161(1):196-210. PubMed ID: 33745946
[TBL] [Abstract][Full Text] [Related]
2. Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer.
Aladhraei M; Kassem Al-Thobhani A; Poungvarin N; Suwannalert P
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3747-3754. PubMed ID: 31870117
[TBL] [Abstract][Full Text] [Related]
3. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
4. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
[TBL] [Abstract][Full Text] [Related]
5. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
7. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
8. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
10. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
11. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
15. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
16. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
18. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
19. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
20. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]